LJPC La Jolla Pharmaceutical Company

8.85
0  0%
Previous Close 8.85
Open
Price To Book 32.78
Market Cap 239,824,185
Shares 27,098,778
Volume 0
Short Ratio
Av. Daily Volume 1,470,048

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 positive interim analysis released June 6, 2019 with top-line data due 2H 2019.
LJPC‑401
Hereditary Hemochromatosis
Pivotal data due mid-2020.
LJPC-401
Beta thalassemia patients suffering from iron overload
PDUFA date under priority review scheduled for February 28, 2018. Approval announced December 21, 2017.
GiaprezaTM (angiotensin II)
Increase blood pressure in adults with septic or other distributive shock
NDA filing due 4Q 2019.
LJPC-0118
Severe Malaria

Latest News

  1. Implied Volatility Surging for La Jolla Pharmaceutical (LJPC) Stock Options
  2. Here's Why La Jolla Pharmaceutical Has More Than Doubled Over the Last 2 Days
  3. How La Jolla Pharmaceutical Company (NASDAQ:LJPC) Can Impact Your Portfolio Volatility
  4. La Jolla Pharmaceutical (LJPC) Reports Q1 Loss, Misses Revenue Estimates
  5. La Jolla Pharmaceutical: 1Q Earnings Snapshot
  6. La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Progress
  7. La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
  8. Consider These 3 Falling Knives
  9. La Jolla Pharmaceutical Company Announces U.S. FDA’s Grant of Breakthrough Therapy Designation for LJPC-0118 for the Treatment of Severe Malaria
  10. La Jolla Pharmaceutical Company Appoints Darryl Wellinghoff as Chief Commercial Officer
  11. Edited Transcript of LJPC earnings conference call or presentation 4-Mar-19 9:30pm GMT
  12. La Jolla Pharmaceutical Company to Present at the 39th Annual Cowen Healthcare Conference
  13. Does La Jolla Pharmaceutical Company’s (NASDAQ:LJPC) CEO Pay Reflect Performance?
  14. Do Options Traders Know Something About La Jolla Pharmaceutical (LJPC) Stock We Don't?
  15. The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings
  16. La Jolla Pharmaceutical Co (LJPC) Q4 2018 Earnings Conference Call Transcript
  17. La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Highlights Recent Corporate Progress and Key Objectives
  18. La Jolla Pharmaceutical Company to Release Fourth Quarter and Full Year 2018 Financial Results on March 4, 2019
  19. La Jolla Pharmaceutical Company Announces Data Presentations at the Society of Critical Care Medicine’s 48th Critical Care Congress
  20. Analysis: Positioning to Benefit within ArcBest, International Game Technology, eHealth, Syros Pharmaceuticals, La Jolla Pharmaceutical, and Virtus Investment Partners — Research Highlights Growth, Revenue, and Consolidated Results